At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Jeremy Thomas, MD, from the Western General Hospital, Edinburgh, United Kingdom, discusses the results of a central pathology review, including tumour type, histological grade and lymphatic invasion, of the SUPREMO trial, a randomised, global phase 3 clinical trial evaluating radiotherapy after mastectomy for patients with intermediate-risk breast cancer.
Pathology quality assurance of SUPREMO trial: Post-mastectomy radiotherapy for breast cancer
14th June 2016
Allergy & Immunology
